# AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

> **NCT05404906** · PHASE2,PHASE3 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 124 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML) in Remission

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Venetoclax
- **OTHER:** Supportive care

## Key facts

- **NCT ID:** NCT05404906
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-25
- **Primary completion:** 2028-06
- **Final completion:** 2030-06
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2022-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05404906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05404906, "AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05404906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*